Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100
Debt
Debt-to-Equity Ratio2.19
Current Ratio1.70
Quick Ratio1.63
Price-To-Earnings
Trailing P/E Ratio17.42
Forward P/E Ratio14.61
P/E Growth1.26
Sales & Book Value
Annual Sales$1.06 billion
Price / Sales3.25
Cash Flow$2.9985 per share
Price / Cash6.87
Book Value$6.05 per share
Price / Book3.40
Profitability
EPS (Most Recent Fiscal Year)$1.18
Net Income$-410,520,000.00
Net Margins-28.02%
Return on Equity19.05%
Return on Assets4.33%
Miscellaneous
Employees1,010
Outstanding Shares166,630,000
Market Cap$3.49 billion
Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Pharma's stock symbol?
Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."
How will Horizon Pharma's stock buyback program work?
Horizon Pharma announced that its Board of Directors has initiated a share repurchase plan on Sunday, June 4th 2017, which authorizes the company to buyback 1,000% of shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.
How were Horizon Pharma's earnings last quarter?
Horizon Pharma PLC (NASDAQ:HZNP) released its earnings results on Wednesday, August, 8th. The biopharmaceutical company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.17. The biopharmaceutical company had revenue of $302.84 million for the quarter, compared to analyst estimates of $275.51 million. Horizon Pharma had a positive return on equity of 19.05% and a negative net margin of 28.02%. The firm's quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.41 EPS. View Horizon Pharma's Earnings History.
When is Horizon Pharma's next earnings date?
What price target have analysts set for HZNP?
11 Wall Street analysts have issued 12 month price objectives for Horizon Pharma's shares. Their predictions range from $16.00 to $25.00. On average, they anticipate Horizon Pharma's share price to reach $20.40 in the next year. This suggests that the stock has a possible downside of 1.0%. View Analyst Price Targets for Horizon Pharma.
What is the consensus analysts' recommendation for Horizon Pharma?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Pharma in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Pharma.
What are Wall Street analysts saying about Horizon Pharma stock?
Here are some recent quotes from research analysts about Horizon Pharma stock:
- 1. Cowen Inc analysts commented, "Sarepta (SRPT) reported 2Q18 sales/earnings and provided a business update on 8/8. Exondys51 sales of $74M topped our expectations (see below) by 5%, and accelerated sequentially in 2Q18, after a slight dip in 1Q18. However, SRPT kept its FY18 guidance unchanged. OPEX is increasing faster than expectations, with FY18E non-GAAP OPEX potentially >2X 2016 levels of $198M. With sales growth starting to slow to high single digits Q/Q, focus is increasingly turning to the early/mid-stage pipeline to deliver commercial products in the near term. We continue to believe that gene therapy projects will take a minimum of 3-5 years to get to market and the exon- skipping agents (53 & 45) on-market by 2020. We stay neutral on the name." (8/9/2018)
- 2. Mizuho analysts commented, "We think the beat was clean, driven by a combination of strong sales, better gross margins, and lower OpEx. Primary care brands beat expectations ($101.1M vs. $85.9M consensus), and Horizon is now reorganizing its segments to segregate this unit from the rest of the company. Krystexxa sales were $58.6M (+53% Y/Y) and also beat consensus expectations of $56.3M. The Teprotumumab trial is now fully enrolled, significantly ahead of schedule, and the company will present its one-year Teprotumumab data at the American Thyroid Association conference (Oct 3-7 in Washington, DC). We will update estimates after the 8 AM call." (8/8/2018)
- 3. According to Zacks Investment Research, "Horizon Pharma’s orphan and rheumatology business units witnessed strong growth. We expect Krystexxa, Ravicti and Actimmune to drive further growth. The acquisition of teprotumumab has further diversified the company’s portfolio. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. In June 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in Europe, the Middle East and Africa to Chiesi Farmaceutici S.p.A. to focus on higher return businesses. Shares of the company have outperformed the industry so far this year." (7/17/2018)
- 4. Cantor Fitzgerald analysts commented, "Message in a bottle/vial. The four doctors we spoke with were positive on the safety and efficacy of Horizon’s Krystexxa. One of the four doctors believed that Krystexxa was a ‘wonder’ drug and was bullish on its growth prospects. The other three doctors were more measured. They all agreed that Krystexxa is a very good drug, but were not convinced it would be widely used among rheumatologists because it works best for a small group of refractory patients. The main barrier to uptake is not anaphylaxis. There are two reasons doctors don’t widely use Krystexxa: 1) the high cost relative to standard of care; 2) because it’s an IV, while the standard of care is oral." (3/14/2018)
Who are some of Horizon Pharma's key competitors?
Some companies that are related to Horizon Pharma include Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS) and GALAPAGOS NV/S (GLPG).
Who are Horizon Pharma's key executives?
Horizon Pharma's management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 51)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 53)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 64)
- Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 48)
- Mr. Miles W. McHugh, Chief Accounting Officer and Sr. VP (Age 53)
Has Horizon Pharma been receiving favorable news coverage?
News articles about HZNP stock have been trending somewhat negative recently, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Horizon Pharma earned a news impact score of 0.00 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 48.58 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Horizon Pharma.
Who are Horizon Pharma's major shareholders?
Horizon Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.15%), Scopia Capital Management LP (7.15%), Dimensional Fund Advisors LP (3.28%), Renaissance Technologies LLC (3.01%), Glenmede Trust Co. NA (1.97%) and Eagle Asset Management Inc. (1.46%). Company insiders that own Horizon Pharma stock include Brian K Beeler, Michael G Grey, Robert Carey and Timothy P Walbert. View Institutional Ownership Trends for Horizon Pharma.
Which institutional investors are selling Horizon Pharma stock?
HZNP stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Millennium Management LLC, Dimensional Fund Advisors LP, Glenmede Trust Co. NA, Bank of New York Mellon Corp, Creative Planning, Cubist Systematic Strategies LLC and First Trust Advisors LP. Company insiders that have sold Horizon Pharma company stock in the last year include Brian K Beeler and Timothy P Walbert. View Insider Buying and Selling for Horizon Pharma.
Which institutional investors are buying Horizon Pharma stock?
HZNP stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., Renaissance Technologies LLC, Bank of America Corp DE, BlackRock Inc., Spark Investment Management LLC, Bellevue Group AG and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Horizon Pharma.
How do I buy shares of Horizon Pharma?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Pharma's stock price today?
One share of HZNP stock can currently be purchased for approximately $20.60.
How big of a company is Horizon Pharma?
Horizon Pharma has a market capitalization of $3.49 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe.
How can I contact Horizon Pharma?
Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Pharma (NASDAQ HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
